Rebif-New Formulation Drug Trial for RRMS

Trial Information

Summary: Quality of Life study for patients with relapsing forms of Multiple Sclerosis who are transitioning from Rebif to Rebif-New Formulation

For persons currently using Rebif to control their Multiple Sclerosis, this study will evaluate their quality of life during the transition to a new investigational formulation of Rebif. Study medication will be provided at no cost to eligible subjects.

Patient Inclusion Criteria

• Diagnosed with a relapsing form of Multiple Sclerosis
• Currently taking Rebif injections three times per week for at least the past 6 months
• Between ages 18-60

Patient Exclusion Criteria

• Treatment with steroids within the past 3 months
• Any other significant medical illness